CYTKClinical Trials•globenewswire•
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Sentiment:Positive (70)
Summary
(NASDAQ:CYTK) Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 30, 2025 by globenewswire